Roche Holding AG

ROG

CH0012032048

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

22/05/2024 - Investor Day

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 09:20 pm IST

Obesity: Roche joins the battle

December 04, 2023 at 09:18 pm IST

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

237.1 CHF

Average target price

279.4 CHF

Spread / Average Target

+17.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	-3.03%	211B
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B
PFIZER, INC.	-0.52%	162B

Other Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 09:00:02 17/05/2024 pm IST			5-day change	1st Jan Change
237.1 ^CHF	+0.98%		+5.33%	-3.03%

17/05	Health Care Up on Rotation to Sector From Rate-Sensitive Groups -- Health Care Roundup	DJ
17/05	ROCHE HOLDINGS AG : UBS sticks Neutral	ZD

Health Care Up on Rotation to Sector From Rate-Sensitive Groups -- Health Care Roundup	18/05	DJ
ROCHE HOLDINGS AG : UBS sticks Neutral	17/05	ZD
Deutsche Bank Upgrades Roche to Hold from Sell	17/05	MT
ROCHE : Deutsche Bank no longer sells	17/05	CF
Roche: share price stands out, Deutsche Bank in support	17/05	CF
ROCHE HOLDINGS AG : Deutsche Bank Upgrades to Neutral	17/05	ZD
Swiss Market Index Rises; Roche Shines on Promising Weight-loss Drug	16/05	MT
Global markets live: Cisco, EasyJet, Roche, Netflix, Amazon...	16/05
Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15	16/05	DP
News Highlights : Top Company News of the Day - Thursday at 9 AM ET	16/05	DJ
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial -- Update	16/05	DJ
Roche Gains as Weight-loss Injection Shows Potential in Early-stage Study	16/05	MT
ROCHE HOLDINGS AG : Receives a Sell rating from JP Morgan	16/05	ZD
News Highlights : Top Company News of the Day - Thursday at 7 AM ET	16/05	DJ
ROCHE HOLDINGS AG : Jefferies remains Neutral	16/05	ZD
European shares slip on auto, energy drag; Siemens drops on bleak earnings	16/05	RE
Roche shares boosted by good results in obesity treatment	16/05	CF
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial	16/05	DJ
Roche shares gain on obesity drug results from early-stage trial	16/05	RE
Roche Says Investigational Obesity Drug Reduces Weight in Early-stage Study	16/05	MT
Swiss Equities Advance as Cool US Inflation Data Boosts Sentiment	15/05	MT
Roche: HPV self-sampling test approved by the FDA	15/05	CF
Roche Wins US FDA Approval for HPV Self-collection Diagnostic Tool	15/05	MT
Roche says FDA approves HPV self-test in US	15/05	RE
Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer	15/05	CI